Portal de Periódicos da CAPES

Comparison of a Phytotherapeutic Agent (Permixon) with an α-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study

2002; Elsevier BV; Volume: 41; Issue: 5 Linguagem: Inglês

10.1016/s0302-2838(02)00066-0

1873-7560

F.M.J. Debruyne, Gary G. Koch, Peter Boyle, Fernando Calais da Silva, Jay G. Gillenwater, Freddie C. Hamdy, Paul B. Perrin, Pierre Teillac, R. Vela‐Navarrete, Jean-Pierre Raynaud,

Pelvic floor disorders treatments

Objective: While the lipido-sterolic extract of Serenoa repens (LSESr)—Permixon®—has been shown to have an equivalent efficacy to finasteride in patients with benign prostatic hyperplasia (BPH), to date, there has been no valid comparison of phytotherapy with α-blockers. The aim of this study was to assess the equivalent efficacy of Permixon and tamsulosin. Methods: Eight hundred and eleven men with symptomatic BPH (I-PSS≥10) were recruited in 11 European countries for a 12-month, double-blind randomized trial. After a 4-week run-in period, 704 patients were randomly assigned to either tamsulosin 0.4 mg/day (N=354) or Permixon 320 mg/day (N=350). I-PSS, QoL and Qmax were evaluated at baseline and periodically for 1 year. Prostate volume and serum prostate-specific antigen (PSA) were measured at selection and at endpoint. The endpoint analysis was performed on the per-protocol population of 542 patients (tamsulosin: N=273; Permixon: N=269). Results: At 12 months, I-PSS decreased by 4.4 in each group and no differences were observed in either irritative or obstructive symptom improvements. The increase in Qmax was similar in both treatment groups (1.8 ml/s Permixon, 1.9 ml/s tamsulosin). PSA remained stable while prostate volume decreased slightly in the Permixon-treated patients. The two compounds were well tolerated, however, ejaculation disorders occurred more frequently in the tamsulosin group. Conclusion: This study demonstrates that Permixon and tamsulosin are equivalent in the medical treatment of lower urinary tract symptoms in men with BPH, during and up to 12 months of therapy.